BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sabatier R, Pierga JY, Curé H, Abulnaja R, Lambaudie E, Bidard FC, Extra JM, Sfumato P, Gonçalves A. Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial. Cancers (Basel) 2021;13:E140. [PMID: 33466225 DOI: 10.3390/cancers13010140] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang J, Zhao Q, Cai L, Li J, Chen S, Lehto V. Efficacy of Bevacizumab and Gemcitabine in Combination with Cisplatin in the Treatment of Esophageal Cancer and the Effect on the Incidence of Adverse Reactions. BioMed Research International 2022;2022:1-6. [DOI: 10.1155/2022/2317181] [Reference Citation Analysis]
2 Jakabova A, Bielcikova Z, Pospisilova E, Petruzelka L, Blasiak P, Bobek V, Kolostova K. Characterization of circulating tumor cells in early breast cancer patients receiving neoadjuvant chemotherapy. Ther Adv Med Oncol 2021;13:17588359211028492. [PMID: 34345252 DOI: 10.1177/17588359211028492] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]